Business

Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025

Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended March 31, 2025 and provide a business and clinical update on May 9, 2025.

articleProtalix Biotherapeutics, Inc. (de)May 5, 20252/company/protalix-biotherapeutics-inc-de/news/protalix-biotherapeutics-to-announce-first-quarter-2025-financial-and-business-results-on-may-9-2025
Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025

About this update from Protalix Biotherapeutics, Inc. (de)

[{"type":"text","content":"Company to host conference call and webcast at 8:30 a.m. EDT","length":60,"tagName":"p","attribs":{}},{"type":"text","content":"CARMIEL, Israel, May 5, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended March 31, 2025 and provide a business and clinical update on May 9, 2025.","length":475,"tagName":"p"},{"type":"image","alt":"Protalix Biotherapeutics Logo","displaySize":"","headline":null,"caption":"Protalix Biotherapeutics Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":121,"url":"https://media.zenfs.com/en/prnewswire.com/f2174d5c59bc5e34e9e5ea6a94c7eeba"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JqTp0X7VmxnrsXQUFDueUg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIxMztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/f2174d5c59bc5e34e9e5ea6a94c7eeba","width":400,"height":121}}},{"type":"text","content":"Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments.","length":142,"tagName":"p"},{"type":"text","content":"Conference Call Details:","length":24,"tagName":"p"},{"type":"text","content":"Date:                    Friday, May 9, 2025Time:                    8:30 a.m. Eastern Daylight Time (EDT)Toll Free:             1-877-423-9813International:      1-201-689-8573Israeli Toll Free:  1-809-406-247Conference ID:    13753682Call me™:            https://tinyurl.com/yey23rkc","length":506,"tagName":"p"},{"type":"text","content":"The Call me™ feature allows you to avoid the wait for an operator; you enter your phone number on the platform and the system calls you right away.","length":147,"tagName":"p"},{"type":"text","content":"Webcast Details: ","length":16,"tagName":"p"},{"type":"text","content":"Company Link:  https://ir.protalix.com/news-events/eventsWebcast Li...

More updates from Protalix Biotherapeutics, Inc. (de)

Protalix BioTherapeuticsbiopharmaceutical companyrecombinant therapeutic proteinsexpression systemplant cellrecombinant proteinstherapeutic proteinsfinancial resultscommercialization